

- Dermatomyositis/polymyositis (DM/PM), 1095-1096
- Designer drugs, 1137
- Desmoplastic reaction, in pancreatic cancer, 599
- Desmopressin (DDAVP), for diabetes insipidus, 632
- Desquamative interstitial pneumonia (DIP), 224
- Developmental disorders, 1027-1029
- Devic's disease, 1005, 1074-1075
- Dexamethasone
 - for bacterial meningitis, 859
 - for cerebral edema, with brain abscess, 862
 - for immune thrombocytopenic purpura, 551
 - for multiple myeloma, 531
 - for vasogenic edema, with brain tumor, 1067
- Dexamethasone-CRH test, 626t
- Dexamethasone suppression test, 631, 647
 - adrenal incidentaloma and, 651
- Dextromethorphan (DXM), 1129t-1130t
- Diabetes
 - gallbladder disease and, 471
 - hypertensive patients with, 176
 - rheumatic manifestations of, 815-816
 - in women, 709
- Diabetes insipidus, 632, 632t
 - polydipsia in, 302
 - water deprivation test in, 632
- Diabetes mellitus, 657-674
 - amyotrophy in, 671
 - autonomic neuropathy and, 990
 - chronic complications of, 670-671
 - chronic kidney disease in, 289, 367
 - comparison of type 1 and type 2, 659t
 - coronary artery disease and, 88
 - definition of, 657
 - diagnostic criteria for, 657, 657t
 - etiologic classification of, 657-658, 658t
 - gastroparesis in, 414-415, 671
 - gestational, 657, 658t, 668
 - hypoglycemia in, 671-674
 - ketoacidosis in, 668-669
 - lumbosacral polyradiculopathy in, 1085
 - management of severe metabolic decompensation in, 668-670
 - nephropathy in, 328, 670
 - neuropathy in, 670-671
 - pancreatitis complicated by, 433
 - retinopathy in, 670
 - sleep apnea with, 245
 - standards of care in, 667-668
 - type 1, 659-663, 659t
 - blood glucose control for, 660-662
 - clinical presentation of, 659-660
 - epidemiology and pathology of, 659, 660f
 - hypoglycemia management for, 662
 - nutritional management for, 662-663
 - treatment of, 660-663
 - type 2, 659t, 663-667
 - blood glucose control for, 665
 - clinical presentation of, 663-664
 - epidemiology and pathology of, 663, 664f
 - exercise in, 667
 - insulin treatment in, 667
 - metabolic syndrome and, 664
 - non-insulin antidiabetic agents in, 665-667, 666t
- Diabetes mellitus (*Continued*)
 - nutritional and weight management for, 667
 - screening for, 663, 665t
 - treatment of, 664-667
- Diabetic foot infections, 889, 889f
 - treatment for, 890
- Diabetic ketoacidosis, 659, 668-669
 - hyperkalemia and, 305
 - metabolic acidosis and, 309
 - symptoms in, 669
 - treatment of, 669
- Diabetic lumbosacral polyradiculopathy, 1085
- Diabetic nephropathy, 328, 328f
- Diabetic neuropathy, 1085
- Dialysis, 366
 - pericarditis and, 365
 - renal osteodystrophy and, 755
- Diamond-Blackfan anemia, 487
- Diaphragm
 - in auscultation, 30-31
 - breathing and, 193
 - function of, ultrasonography of, 203, 204f
 - paralysis of, 252-253
 - fluoroscopy of, 203, 253
- Diarrhea, 384-388
 - acute, 384-386
 - AIDS-associated, 938t
 - chronic, 386-388
 - classification of, 384t
 - definition of, 384
 - diabetic neuropathy with, 671
 - from enteral feeding, 686
 - in HIV-infected patients, 938
 - infectious, 899-904
 - from bacterial food poisoning, 900
 - clinical presentation of, 900t, 902
 - cytotoxin-induced, 899
 - definition and epidemiology of, 899
 - diagnosis and differential diagnosis of, 902-903, 903f
 - enterotoxin-induced, 899
 - invasive, 900
 - pathology of, 899-900
 - prognosis of, 904
 - protozoan causes of, 902
 - specific pathogens in, 900-902, 900t-901t
 - treatment of, 903-904
 - viral causes of, 902
 - in inflammatory bowel disease, 423
 - malabsorptive therapy for, 384
 - metabolic acidosis and, 308
 - physiology of, 384
 - potassium losses and, 303
- Diarrheal hemolytic-uremic syndrome, 349
- Diastole, 16, 19
- Diastolic dysfunction, 22
 - in systemic sclerosis, 790
- Diastolic murmur, 34-35
 - in ventricular septal defects, 69
- Diastolic rumbles, 34-35
- Diatrizoate, 392-393
- DIC. *see* Disseminated intravascular coagulation (DIC).
- Dicrotic notch, 29
- Diet
 - in chronic kidney disease, 367
 - for diabetic patients, 662-663
 - hyperkalemia and, 305
 - for hyperlipidemia, 693
 - hyperoxaluria and, 339
 - hypokalemia and, 303
 - for obesity, 678
- Dietary therapy, for epilepsy, 1060
- Diffuse alveolar damage (DAD), 232
- Diffuse alveolar hemorrhage, 232-233
- Diffuse esophageal spasm, 400t
- Diffuse idiopathic skeletal hyperostosis (DISH), 816
- Diffuse large B-cell lymphoma (DLBCL), 522
- Diffuse Lewy body disease, 982
- Diffuse panbronchiolitis, 215
- Diffusion capacity for carbon monoxide (DLCO), 188, 202
 - in lung cancer, 269
 - measurement of, 202, 202.e1f
- Diffusion impairment, alveolar, 199
- Digital ulcerations, systemic sclerosis and, 791
- Digoxin
 - as antiarrhythmic agent, 115
 - for heart failure, 64
- Dihydropyridines, for angina pectoris, 95
- 1,25-Dihydroxyvitamin D₃, in acute kidney injury, 361.e1t
- Dilated cardiomyopathy, 140-142, 141t
 - peripartum, 157
- Dimethyl fumarate, for multiple sclerosis, 1073
- Dipeptidyl peptidase-4 (DPP-4) inhibitors, for type 2 diabetes, 666-667, 666t
- Diplopia, monocular, 1004
- Dipyridamole
 - aspirin with, for stroke prevention, 1044
 - as vasodilator, 45
- Direct fluorescent antibody staining, 830-831
- Direct renin inhibitors, 173t
 - contraindications and side effects of, 174t
- Direct smear interpretation, 830-831, 831f
- Direct thrombin inhibitors, in heparin-induced thrombocytopenia, 569
- Disease markers, of liver disease, 441-442
- Disease-modifying antirheumatic drugs (DMARDs), for rheumatoid arthritis, 773, 774t
- Disease-modifying genes, 12
- Disopyramide, 113, 115t
- Disseminated intravascular coagulation (DIC), 553, 553t
 - cryoprecipitate for, 562
 - in malignancies, 568
 - microangiopathic hemolysis caused by, 509
 - in sepsis, 850
- Dissociative drugs, 1129t-1130t, 1136
- Distal sodium delivery, primary increase in, 303-304
- Disulfiram (Antabuse), 1131
- Diuretic Optimization Strategies Evaluation (DOSE) trial, 61-62
- Diuretics
 - in acute severe regurgitation, 80
 - contraindications to, 174t
 - cyanotic congenital heart and, 279